article · Pharmaceuticals
Hypoxia-inducible factor-1 serves as a fundamental regulator of cellular oxygen balance and mediates the cellular response to low oxygen levels. In cancer, the HIF-1alpha subunit is significantly elevated, driving tumour survival through various mechanisms. Beyond promoting cell survival, this transcription factor influences key stages of tumour progression, including cell division, proliferation, the formation of new blood vessels, and metastasis. It also controls critical metabolic adaptations in cells, notably the anaerobic metabolism of glucose. Because of these widespread contributions to malignancy, targeting this pathway has emerged as an active area of oncology research. Multiple therapeutic compounds directed at processes associated with this regulator are currently utilised in treating diverse forms of cancer. Emerging therapeutic interventions focus on regulating these pathways, with nanotechnology increasingly employed to advance and support these treatment strategies.
Low oxygen environments are common in tumours, allowing cancer cells to survive, grow, and spread. Understanding and interfering with the primary mechanisms regulating oxygen response helps in designing more effective treatments. Insights into these pathways and the integration of nanotechnology assist in halting tumour progression and targeting the unique metabolic weaknesses of cancer cells.
The findings are relevant to pharmaceutical and biotechnology developers working on cancer therapies that target hypoxia and tumour metabolism. While several compounds targeting these pathways are already used in clinical cancer treatment, strategies incorporating nanotechnology represent early-stage research aimed at enhancing therapeutic development and delivery.
AI-generated from the published abstract. Always read the original work before citing.
Hypoxia-inducible factor-1 (HIF-1) is a key regulator for balancing oxygen in the cells. It is a transcription factor that regulates the expression of target genes involved in oxygen homeostasis in response to hypoxia. Recently, research has demonstrated the multiple roles of HIF-1 in the pathophysiology of various diseases, including cancer. It is a crucial mediator of the hypoxic response and regulator of oxygen metabolism, thus contributing to tumor development and progression. Studies showed that the expression of the HIF-1α subunit is significantly upregulated in cancer cells and promotes tumor survival by multiple mechanisms. In addition, HIF-1 has potential contributing roles in cancer progression, including cell division, survival, proliferation, angiogenesis, and metastasis. Moreover, HIF-1 has a role in regulating cellular metabolic pathways, particularly the anaerobic metabolism of glucose. Given its significant and potential roles in cancer development and progression, it has been an intriguing therapeutic target for cancer research. Several compounds targeting HIF-1-associated processes are now being used to treat different types of cancer. This review outlines emerging therapeutic strategies that target HIF-1 as well as the relevance and regulation of the HIF-1 pathways in cancer. Moreover, it addresses the employment of nanotechnology in developing these promising strategies.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/ph17020195
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
